Ivermectin reduces risk for COVID-19 with very high confidence for mortality, ventilation, ICU admission, hospitalization, progression, recovery, cases, viral clearance, and in pooled analysis. We show traditional outcome specific analyses and combined evidence from all studies, incorporating treatment delay, a primary confounding factor in COVID-19 studies. Real-time updates and corrections, transparent analysis with all results in the same format, consistent protocol for 42 treatments. 83 ivermectin COVID-19 controlled studies, 34 RCTs 63% improvement for early treatment, R 0.37 (0.29-0.48] Probability results from ineffective treatment (since 25 Mar 2021): under 1 in 1 billion